drugset / Trial / NCT02112552

Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer

NCT02112552 ↗

NaSingle-groupOpen-labelTreatment

Summary

This pilot, phase II trial studies the side effects and how well paclitaxel given into the vein and carboplatin given directly into the abdominal cavity (intraperitoneally) followed by radiation therapy work in treating patients with stage IIIC-IV serous uterine cancer. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, stopping them from dividing, or stopping them from spreading. Giving the drugs in different ways may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy followed by radiation therapy may be an effective treatment for uterine cancer.

Timeline

Start
2014-04-10
Primary completion
2016-08
Completion
2017-12-01

Outcome

Outcome not reported

Stopped (Enrollment): “Low accrual. Study formally terminated by PI on 12/1/2017”

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule — Intrathecal
Subject Paclitaxel Small molecule — Intravenous